SEC	Form	4
-----	------	---

Γ

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1	Check this box if no longer subject to
L	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)
4	may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer ENO Robert Paul . Issuer Name and Ticker or Trading Symbol Director 10% Owner (Last) (First) (Middle) . Date of Earliest Transaction (Month/Day/Year) Officer (give title Other (specify below) Other (specify below) 2118 WALSH AVENUE, SUITE 210 . If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) SANTA CLARA CA 95050 . If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) (City) (State) (Zip) . Zip . If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)			Table I - Non-Der	ivative Securities Acquired, Disposed of, or Beneficia	lly Owned				
ENO Robert Paul HeartBeam, Inc. [BEAT] (Check all applicable) (Last) (First) (Middle) 2118 WALSH AVENUE, SUITE 210 Director 10% Owner (Street) 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person	(City)	(State)	(Zip)						
ENO Robert Paul HeartBeam, Inc. [BEAT] Director 10% Owner 3. Date of Earliest Transaction (Month/Day/Year) 08/02/2023 Officer (give title below) Other (specify below)	· /	СА	95050	4. If Amendment, Date of Original Filed (Month/Day/Year)	X Form filed by One Reporting Person				
ENO Robert Paul HeartBeam, Inc. [BEAT] (Check all applicable) 3. Date of Earliest Transaction (Month/Day/Year) Director 10% Owner x Officer (give title Other (specify	2118 WALSH AVENUE, SUITE 210				President				
	,			3. Date of Earliest Transaction (Month/Day/Year)	V Officer (give title Other (specify				
)* 						

······································	Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (In 8)		Disposed Of (D) (Instr. 3, 4 and 5)		Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount (A) or (D) Price		(Instr. 3 and 4)		(1150.4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		Form: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v			Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		
Stock option (right to buy)	\$2.9	08/02/2023		Α		357,000 ⁽¹⁾		08/02/2023 ⁽²⁾	08/02/2033	Common Stock	357,000	\$ <mark>0</mark>	536,000	D	

Explanation of Responses:

1. The options ("Option" and collectively, "Options") have been issued from the Company's 2022 Equity Incentive Plan, that was approved by the Members of the Board of Directors on August 1, 2023.

2. The Options will vest and become exercisable with respect to 40% of the shares starting August 1, 2023, with one forty-eighth (1/48th) of the shares vesting each calendar month thereafter on the same day of the month as the first vesting date. The remaining 60% of the shares will vest and become exercisable once HeartBeam, Inc. receives FDA Clearance for marketing of HeartBeam's synthesized 12-Lead product obtained by signal synthesis from the recorded xyz signals.

/s/ Robert Paul Eno

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

08/04/2023 Date